Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Distribution of GLP-1 and PACAP receptors in human tissues.

× No keyword cloud information.

21 in total

Review 1. Glucagon-like peptide 1 (GLP-1).

Authors: T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal: Mol Metab Date: 2019-09-30 Impact factor: 7.422

Review 2. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study.

Authors: Kenneth B Margulies; Kevin J Anstrom; Adrian F Hernandez; Margaret M Redfield; Monica R Shah; Eugene Braunwald; Thomas P Cappola
Journal: Circ Heart Fail Date: 2014-07 Impact factor: 8.790

3. GLP-1 receptor is expressed in human stomach mucosa: analysis of its cellular association and distribution within gastric glands.

Authors: Efrat Broide; Olga Bloch; Gilad Ben-Yehudah; Dror Cantrell; Haim Shirin; Micha J Rapoport
Journal: J Histochem Cytochem Date: 2013-06-26 Impact factor: 2.479

4. Mitochondrial dysfunction and its impact on diabetic heart.

Authors: Suresh Kumar Verma; Venkata Naga Srikanth Garikipati; Raj Kishore
Journal: Biochim Biophys Acta Mol Basis Dis Date: 2016-09-01 Impact factor: 5.187

5. Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy.

Authors: Siva Bhashyam; Anjali V Fields; Brandy Patterson; Jeffrey M Testani; Li Chen; You-Tang Shen; Richard P Shannon
Journal: Circ Heart Fail Date: 2010-05-13 Impact factor: 8.790

Distribution of GLP-1 and PACAP receptors in human tissues.

Review 1. Glucagon-like peptide 1 (GLP-1).

Review 2. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study.

3. GLP-1 receptor is expressed in human stomach mucosa: analysis of its cellular association and distribution within gastric glands.

4. Mitochondrial dysfunction and its impact on diabetic heart.

5. Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy.

6. [Incretins: do they exert cardiovascular effects?].

7. Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter.

8. Treatment of patients with diabetes with GLP-1 analogues or DPP-4- inhibitors: a hot topic for cardiologists?

9. Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.

10. Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.